Cannabidiol inhibits lung proliferation in monocrotaline-induced pulmonary hypertension in rats

Cannabidiol inhibits lung proliferation in monocrotaline-induced pulmonary hypertension in rats

Cannabidiol (CBD) is a safe and well-tolerated plant-derived drug with anti-proliferative properties. Pulmonary hypertension (PH) is a rapidly progressive and still incurable disease. CBD diminishes monocrotaline (MCT)-induced PH, including reduced right ventricular systolic pressure, pulmonary vasc...

Full description

Bibliographic Details
Main Authors:	Anna Krzyżewska, Marta Baranowska-Kuczko, Irena Kasacka, Hanna Kozłowska
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Pulmonary hypertension Cannabidiol Monocrotaline Animal model Fibrosis Lung fibrosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332223000227

Similar Items

Cannabidiol Improves Antioxidant Capacity and Reduces Inflammation in the Lungs of Rats with Monocrotaline-Induced Pulmonary Hypertension
by: Anna Krzyżewska, et al.
Published: (2022-05-01)

Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
by: Olga Sadowska, et al.
Published: (2020-09-01)

Comparative analysis of age in monocrotaline-induced pulmonary hypertensive rats
by: Akiko Kawade, et al.
Published: (2021-09-01)

Subchronic toxicity of the pulmonary hypertension model due to low-dose monocrotaline in rats
by: Vicente Benavides-Cordoba, et al.
Published: (2020-07-01)

A potential model of systemic sclerosis with pulmonary hypertension induced by monocrotaline plus bleomycin
by: Xia Fang, et al.
Published: (2022-08-01)

Protective effect of triclosan in monocrotaline-induced pulmonary arterial hypertension: FASN inhibition a novel approach
by: Nimer Alsabeelah, et al.
Published: (2022-01-01)

An inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotaline-induced pulmonary hypertensive rats model
by: Jung Hyun Kwon, et al.
Published: (2013-03-01)

Preventive treatment with atorvastatin ameliorates endothelial dysfunction of small pulmonary arteries in monocrotaline-induced pulmonary hypertensive rats
by: Zhihong Lin, et al.
Published: (2017-08-01)

Ameliorative Effects of Beetroot Juice Supplementation on Monocrotaline-Induced Pulmonary Hypertension in Rats
by: Masashi Tawa, et al.
Published: (2022-11-01)

Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters
by: Tomas Jasenovec, et al.
Published: (2022-10-01)

Fermented garlic extract ameliorates monocrotaline-induced pulmonary hypertension in rats
by: Byung Mun Park, et al.
Published: (2017-03-01)

Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal
by: Mario Udovicic, et al.
Published: (2021-07-01)

Lung damage created by high tidal volume ventilation in rats with monocrotaline-induced pulmonary hypertension
by: Masako Kawai, et al.
Published: (2022-03-01)

Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension
by: Eva Malikova, et al.
Published: (2022-02-01)

Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension
by: Yifan Zuo, et al.
Published: (2024-03-01)

Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition
by: Yonghui Wu, et al.
Published: (2021-07-01)

STUDY OF THE PHARMACOLOGICAL ACTIVITY OF LOWMOLECULAR ARGINASE II SELECTIVE INHIBITOR USING A MODEL OF MONOCROTALINE-INDUCED PULMONARY HYPERTENSION
by: Liliya V. Korokina, et al.
Published: (2019-03-01)

Monocrotaline Induces Endothelial Injury and Pulmonary Hypertension by Targeting the Extracellular Calcium–Sensing Receptor
by: Rui Xiao, et al.
Published: (2017-04-01)

Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice
by: Balram Neupane, et al.
Published: (2020-06-01)

The EPOR/CD131 heteroreceptoragonist has an endothelioprotective effect against the background of pulmonary hypertension caused by monocrotalin
by: Lilia V. Korokina
Published: (2023-11-01)

Congestive Hepatopathy Secondary to Right Ventricular Hypertrophy Related to Monocrotaline-Induced Pulmonary Arterial Hypertension
by: Douglas Mesadri Gewehr, et al.
Published: (2021-11-01)

Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension
by: Anna Krzyżewska, et al.
Published: (2021-09-01)

Beneficial effects of berberine against pulmonary complications of experimental pulmonary arterial hypertension in rats and some relevant mechanisms
by: Ahmad Beik, et al.
Published: (2023-01-01)

Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects
by: Ahmad Beik, et al.
Published: (2021-04-01)

Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis
by: Mengdi Sun, et al.
Published: (2024-02-01)

The zinc transporter ZIP12 regulates monocrotaline-induced proliferation and migration of pulmonary arterial smooth muscle cells via the AKT/ERK signaling pathways
by: Chaoyi Ye, et al.
Published: (2022-03-01)

Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension
by: Marta Baranowska-Kuczko, et al.
Published: (2021-10-01)

Protective Effects of 18β-Glycyrrhetinic Acid on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
by: Min Zhang, et al.
Published: (2019-01-01)

The siRNA-mediated knockdown of AP-1 restores the function of the pulmonary artery and the right ventricle by reducing perivascular and interstitial fibrosis and key molecular players in cardiopulmonary disease
by: Ioana Karla Comarița, et al.
Published: (2024-02-01)

Decreased Expression of Canstatin in Rat Model of Monocrotaline-Induced Pulmonary Arterial Hypertension: Protective Effect of Canstatin on Right Ventricular Remodeling
by: Akira Sugiyama, et al.
Published: (2020-09-01)

Experimental animal models of pulmonary hypertension: Development and challenges
by: Xiao‐Han Wu, et al.
Published: (2022-06-01)

Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
by: Toshikazu Ito, et al.
Published: (2021-11-01)

Formulation and Characterization of Solid Lipid Nanoparticles Loading RF22-c, a Potent and Selective 5-LO Inhibitor, in a Monocrotaline-Induced Model of Pulmonary Hypertension
by: Angela Liparulo, et al.
Published: (2020-02-01)

Therapeutic Evaluation of Antibody-Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension
by: Baptiste Gouyou, et al.
Published: (2021-03-01)

Downregulation of Soluble Guanylate Cyclase and Protein Kinase G With Upregulated ROCK2 in the Pulmonary Artery Leads to Thromboxane A2 Sensitization in Monocrotaline-Induced Pulmonary Hypertensive Rats
by: Suhan Cho, et al.
Published: (2021-02-01)

Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB /p38 pathway
by: Lei Gao, et al.
Published: (2018-03-01)

Pulmonary hypertension associated with chronic lung diseases
by: Manuela Funke, et al.
Published: (2016-09-01)

Incidence and Clinical Characteristics of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
by: Wei Yan, et al.
Published: (2015-01-01)

Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights
by: Grégoire Ruffenach, et al.
Published: (2020-11-01)

Chronic and moderate consumption of reduced-alcohol wine confers cardiac benefits in a rat model of pulmonary arterial hypertension
by: Patrick Diaba-Nuhoho, et al.
Published: (2021-08-01)